Aayushi Mahajan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9079950/publications.pdf

Version: 2024-02-01

1163117 1281871 27 894 8 11 citations g-index h-index papers 32 32 32 1762 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 2019, 25, 462-469.	30.7	569
2	HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models. Journal of Clinical Investigation, 2020, 130, 3699-3716.	8.2	104
3	Integrin signaling potentiates transforming growth factor-beta 1 (TGF- $\hat{1}^2$ 1) dependent down-regulation of E-Cadherin expression $\hat{a} \in \text{MT}$ in renal cell carcinoma. Experimental Cell Research, 2017, 355, 57-66.	2.6	44
4	Aurora kinase A inhibition reverses the Warburg effect and elicits unique metabolic vulnerabilities in glioblastoma. Nature Communications, 2021, 12, 5203.	12.8	38
5	CD8+ T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clinical Cancer Research, 2020, 26, 4390-4401.	7.0	36
6	MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma. Cancer Research, 2020, 80, 30-43.	0.9	35
7	Ribosomal protein S11 influences glioma response to TOP2 poisons. Oncogene, 2020, 39, 5068-5081.	5.9	21
8	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. Clinical Cancer Research, 2021, 27, 5669-5680.	7.0	4
9	Human Induced Pluripotent Stem Cell Models of Frontotemporal Dementia With Tau Pathology. Frontiers in Cell and Developmental Biology, 2021, 9, 766773.	3.7	4
10	TAMI-57. INDUCTION OF FERROPTOSIS PROMOTES IMMUNOGENIC CELL DEATH AND ACTIVATION OF THE IMMUNE MICROENVIRONMENT IN GLIOMA. Neuro-Oncology, 2021, 23, vi210-vi210.	1.2	2
11	TMOD-37. IN VIVO SYNERGISTIC EFFECT OF CHECKPOINT BLOCKADE AND RADIATION THERAPY AGAINST CHORDOMAS IN A HUMANIZED MOUSE MODEL. Neuro-Oncology, 2018, 20, vi276-vi276.	1.2	1
12	Abstract B165: Investigating in vivo synergistic effect of checkpoint blockade and radiation therapy against chordomas in a humanized mouse model., 2019,,.		1
13	GENE-08. PHARMACOLOGIC MODULATION OF MYC AND PDGFRA BY TARGETING TOPOISOMERASE II ON GLIOMAS. Neuro-Oncology, 2017, 19, vi94-vi94.	1.2	0
14	GENE-17. TOP2B REGULATES CDK4 SPLICE VARIANTS IN GLIOMAS. Neuro-Oncology, 2018, 20, vi106-vi106.	1.2	0
15	DDIS-13. UNDERSTANDING GLIOBLASTOMA SUSCEPTIBILITY TO TOP2-TARGETING DRUGS FOR PERSONALIZED THERAPY. Neuro-Oncology, 2018, 20, vi71-vi72.	1.2	0
16	144 In Vivo Synergistic Effect of Checkpoint Blockade and Radiation Therapy Against Chordomas in a Humanized Mouse Model. Neurosurgery, 2018, 65, 95-96.	1.1	0
17	Friday, September 28, 2018 10:30 AM–12:00 PM abstracts: innovation, surface technology and biomechanics. Spine Journal, 2018, 18, S90.	1.3	0
18	IMMU-42. CD8+ T-CELLS MEDIATE IMMUNOEDITING, AND INFLUENCE GENOTYPE, TUMOR ONCOGENIC PATHWAYS AND MICROENVIRONMENT DURING PROGRESSION OF MURINE GLIOMAS. Neuro-Oncology, 2019, 21, vi128-vi128.	1.2	0

#	Article	IF	CITATIONS
19	ETMM-04. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA MODEL SYSTEMS. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	0
20	ETMM-05. LACTIC ACID FACILITATES GLIOBLASTOMA GROWTH THROUGH MODULATION OF THE EPIGENOME. Neuro-Oncology Advances, 2021, 3, i15-i15.	0.7	0
21	Abstract 5103: Notch is a master regulator of mesenchymal transformation and therapeutic resistance in glioma. , 2018, , .		0
22	TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas. SSRN Electronic Journal, 0, , .	0.4	0
23	Novel Pineal Germinoma Model Demonstrates Sensitivity to MTOR Inhibition. , 2020, 81, .		0
24	TAMI-70. METABOLIC VULNERABILITY TO GPX4 INHIBITION AND FERROPTOSIS OF QUIESCENT ASTROCYTE-LIKE GLIOMA CELL POPULATIONS. Neuro-Oncology, 2021, 23, vi212-vi213.	1.2	0
25	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii47-ii48.	1.2	0
26	TAMI-33. AURKA INHIBITION REPROGRAMS METABOLISM AND IS SYNTHETICALLY LETHAL WITH FATTY ACID OXIDATION INHIBITION IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii220-ii220.	1.2	0
27	EPCO-16. LACTIC ACID IS AN EPIGENETIC METABOLITE THAT DRIVES GLIOBLASTOMA SURVIVAL AND GROWTH. Neuro-Oncology, 2020, 22, ii72-ii72.	1.2	0